General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection


Cite item

Full Text

Abstract

The lecture considers a number of molecular and cellular mechanisms underlying the structural and functional rearrangement and development of renal and cardiac fibrosis in chronic kidney disease (CKD). It details the key component of disadaptative organ remodeling (the formation of myofibroblasts via epithelial-mesenchymal and endothelial-mesenchymal transdifferentiation) and the role of leading angiofibrogenic mediators (angiotensin II, transforming growth factor-Β type 1, a plasminogen activator inhibitor type 1, etc.) in the regulation of these processes. Investigation of the molecular and cellular bases of organ fibrosis, including the factors of dysregulated activation, differentiation and survival of microfibroblasts, makes it possible to specify the mechanisms of action of traditional nephro- and cardioprotective agents, to offer a possibility for a goal-oriented (target) effect on individual fibrogenic components, and to expand the arsenal of medications suppressing renal and cardiac remodeling.

About the authors

L V Kozlovskaia

Первый МГМУ им. И.М. Сеченова Минздрава России

Email: irbo.mma@mail.ru

I N Bobkova

НИИ уронефрологии и репродуктивного здоровья человека Первого МГМУ им. И.М. Сеченова Минздрава России

Email: irbo.mma@mail.ru

M L Nanchikeeva

Областная клиническая больница, Владимир

Email: dom@mbulanov.elcom.ru

N V Chebotareva

НИИ уронефрологии и репродуктивного здоровья человека Первого МГМУ им. И.М. Сеченова Минздрава России

Email: natasha_tcheb@mail.ru

O A Li

НИИ уронефрологии и репродуктивного здоровья человека Первого МГМУ им. И.М. Сеченова Минздрава России

Email: shoa78@bk.ru

O K Plieva

Первый МГМУ им. И.М. Сеченова Минздрава России

References

  1. Kalluri R., Neilson E.G. Epithelial-mesenchymal transitition and its implication for fibrosis. J Clin Invest 2003; 112 (12): 1776-1784.
  2. Yoshimatsu Y., Watabe T. Role of TGF-Β1 signals in endothelial-mesenchymal transitition in cardiac fibrosis. Intern J Inflam 2011;2011:724080. doi: 10.4061/2011/724080. Epub 2011 Nov 30.
  3. Zeisberg M., Neilson E.G. Biomarkers for epithelial-to-mesenchymal transitition. J Clin Invest 2009; 119 (6): 1429-1437.
  4. Leask A. Potential therapeutic targets for cardiac fibrosis: TGF-Β, angiotensin, endothelin, CCN2 and PDGF? Partners of fibroblast activation. Circul Res 2010; 106 (11): 1675-1680.
  5. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
  6. Eddy A.A., Fogo А.В. Plasminogen activator inhibitor-1in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
  7. Takeda N., Manabe I. Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. Intern J Inflam 2011; 2011: 535241. doi: 10.4061/2011/535241. Epub 2011 Sep 18.
  8. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255-278.
  9. Zeisberg E.M., Tarnavski O., Zeisberg M. et al. Endothelial-to-mesenchymal transitition contributes to cardiac fibrosis. Nature Med 2007; 13 (8): 952-961.
  10. Liu Y. New insights into epithelial-mesenchymal transitition contribute in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222.
  11. Zeisberg E.M., Kalluri R. Epithelial-to-mesenchymal transitition contributes in renal fibrosis. J Molecul Med 2004; 82 (3): 175-181.
  12. Kriz W., Greitz N., Lemley K.V. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
  13. Lemley K.V., Lafayette A., Safai G. et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485.
  14. Galichon P., Hertig A. Epithelial to mesenchymal transitition a biomarker in renal fibrosis: are we ready for bedside? Fibrogenes Tissue Repair 2011; 4: 11-17.
  15. Kriz W., Kaissling B., Le Hir M. Epithelial-mesenchymal transitition in kidney fibrosis: fact or fantasy? J Clin Invest 2011; 121: 468-472.
  16. Мухин Н.А., Козловская Л.В., Бобкова И.Н. и др. Индуцируемые протеинурией механизмы ремоделирования тубулоинтерстиция и возможности нефропротекции при гломерулонефрите. Вестн РАМН 2005; 1: 3-8.
  17. Козловская Л.В., Бобкова И.Н., Плиева О.К. и др. Значение исследования в моче молекулярных медиаторов иммунного воспаления и фиброза в почке при хроническом гломерулонефрите. Тер арх 2004; 9: 84-87.
  18. Нанчикеева М.Л., Конечная Е.Я., Буланов М.Н. и др. Возможности ранней диагностики поражения почек у больных гипертонической болезнью. Тер арх 2004; 9: 29-34.
  19. Бобкова И.Н., Чеботарева Н.В., Козловская Л.В. и др. Экскреция с мочой моноцитарного хемотаксического протеина-1 и трансформирующего фактора роста Β1 как показатель прогрессирования хронического гломерулонефрита. Тер арх 2006; 5: 9-14.
  20. Schrijvers B.F., Flyvbjerg A., De Vriese A.S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65 (6): 2003-2017.
  21. Fogo A.B., Kon V. The glomerulus - a view from the inside-the endothelial cell. Int J Biochem Cell Biol 2010; 42 (9): 1388-1397.
  22. Ли О.А., Бобкова И.Н., Козловская Л.В. Клиническое значение определения матриксных металлопротеиназ и их ингибиторов в моче больных хроническим гломерулонефритом. Тер арх 2009; 8: 10-14.
  23. Li O., Bobkova I., Kozlovskaya L., Varshavskiy V. Matrix metalloproteinases (MMP) and its inhibitors in chronic glomerulonephritis (CGN): association with clinical activity and proteinuric remodeling of renal tubulointerstitium. Nephrol Dial Transplant Plus 2010; 1 (3): 375.
  24. Cheng S., Lovett D.H. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937-1949.
  25. Fogo A.B. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35: 179-188.
  26. Ruiz-Ortega M., Ruperez M., Esteban V. et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney disease. Nephrol Dial Transplant 2006; 21: 16-20.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies